The yeast Cdc7 function is required for the G1/S transition and is dependent on passage through START, a point controlled by the Cdc28/cdc2/p34 protein kinase. CDC7 encodes a protein kinase activity, and we now show that this kinase activity varies in the cell cycle but that protein levels appear to remain constant. We present several lines of evidence that periodic activation of CDC7 kinase is at least in part through phosphorylation. First, the kinase activity of the Cdc7 protein is destroyed by dephosphorylation of the protein in vitro with phosphatase. Second, Cdc7 protein is hypophosphorylated and inactive as a kinase in extracts of cells arrested at START but becomes active and maximally phosphorylated subsequent to passage through START. The phosphorylation pattern of Cdc7 protein is complex. Phosphopeptide mapping reveals four phosphopeptides in Cdc7 prepared from asynchronous yeast cells. Both autophosphorylation and phosphorylation in trans appear to contribute to this pattern. Autophosphorylation is shown to occur by using a thermolabile Cdc7 protein. A protein in yeast extracts can phosphorylate and activate Cdc7 protein made in Escherichia coli, and phosphorylation is thermolabile in cdc28 mutant extracts. Cdc7 protein carrying a serine to alanine change in the consensus recognition site for Cdc28 kinase shows an altered phosphopeptide map, suggesting that this site is important in determining the overall Cdc7 phosphorylation pattern.
INTRODUCTION
The eukaryotic cell cycle is composed of two major events, S phase, during which the chromosomes are replicated, and M phase, during which the chromosomes are segregated. These two portions of the cycle are separated by gaps called Gl and G2, which are devoted to regulating the transitions between replication and segregation. During G1, the events leading to chromosome duplication are monitored and executed. Checkpoints ensuring completion of DNA synthesis and readiness for nuclear division occur in G2 (Hartwell and Weinert, 1989) . In the past few years, significant breakthroughs have been made in determining the molecular events that regulate and promote entry into M phase (Dunphy and Newport, 1988a; Lewin, 1990) . A key regulatory molecule in this process is highly conserved in eukaryotes, namely, the p34/cdc2+/MPF (mitosis promoting factor) protein kinase subunit (Dunphy and Newport, 1988b) . Because much less is known about the events leading to the initiation of nuclear DNA replication at the G1/S transition, we have undertaken studies of this phase of the cell cycle.
In unicellular organisms such as yeast (Saccharomyces cerevisiae, Schizosaccharomyces pombe), the major control point in Gl is called START, which may or may not correspond to the "restriction point" in mammalian cells (Pringle and Hartwell, 1981; Pardee, 1989) . START defines the point in the cycle after which the cell is committed to a round of DNA synthesis and no longer can undergo the alternative developmental program of conjugation. Several yeast mutants, the best studied of which is cdc28, arrest at a point in Gl at which conjugation is still possible and thus are said to affect START (Reed, 1980; Pringle and Hartwell, 1981) . CDC28 encodes the homolog of the p34/cdc2+/MPF protein kinase subunit . Thus it appears that the same protein kinase is involved in regulating both the Gl/S and G2/M transitions during the yeast cell cycle (Nurse and Bissett, 1981; Piggott et al., 1982; Ghiara et al., 1991; Surana et al., 1991) .
We have very little information on the molecular nature of the events set in motion by CDC28 and the other START genes. Although the commitment to DNA synthesis is made by passage through START, DNA synthesis does not begin immediately. A number of addi-tional genetically defined steps must occur before the onset of DNA replication. It is likely that both induction of the genes encoding replication proteins and posttranslational activation of replication proteins are preconditions for the initiation of DNA synthesis. The CDC28, CDC4, and CDC7 genes are thought to define one series of steps that must be completed before the initiation of DNA synthesis (Hartwell, 1976; Pringle and Hartwell, 1981) . CDC28 encodes a protein kinase, CDC4 encodes a protein with homology to the b-subunit of transducin and the ets oncogene (Peterson et al., 1984; Fong et al., 1986 ) and CDC7 encodes a protein kinase (Patterson et al., 1986; Sclafani, 1990; Yoon and Campbell, 1991) . Though these activities suggest a signal transduction cascade, little information is available about their functional interrelationships.
Our focus has been to determine the biochemical basis for the position of the Cdc7 protein in the putative Gl regulatory cascade. The CDC7 controlled events have been shown genetically to depend on completion of START, because the CDC7 step cannot be completed during block of cells with the mating pheromone afactor, which like cdc28 mutations, arrests cells at START (Hereford and Hartwell, 1974) . The Cdc7 protein is thought to execute its function late in Gl, since cells carrying a thermosensitive (ts) cdc7 mutation arrest mitotic growth at the Gl/S phase boundary at the restrictive temperature, just before the initiation of DNA synthesis (Hartwell, 1973 (Hartwell, , 1976 . These cells show a dumbbell shaped terminal phenotype typically associated with a DNA synthesis or nuclear division defect (Hartwell, 1973) . Another reason for placing CDC7 function very late in Gl is the fact that cdc28 and cdc4 mutants blocked at the nonpermissive temperature and then returned to the permissive temperature in the presence of the protein synthesis inhibitor cycloheximide do not progress further through the cycle and do not enter S phase, whereas cdc7 mutants treated in the same way enter S phase and complete DNA synthesis in the presence of protein synthesis inhibitors (Hereford and Hartwell, 1974) . Further protein synthesis is thus necessary for the initiation of DNA synthesis after CDC28 and CDC4, whereas all of the proteins essential for DNA replication appear to be present at the CDC7 stage. The crucial proteins required have not yet been identified, but the cyclins are likely to be among them . CDC7 thus mimics the final stage of the "restriction point" in mammalian cells, insofar as it was defined as the point in the cell cycle after which no further protein synthesis is necessary for initiation of DNA synthesis. Thus CDC7 may define a second, post-START commitment point in the yeast cell cycle. Evidence suggesting the presence of Cdc7 protein in a putative DNA replication complex has been presented (Jazwinski, 1988 ).
-In contrast to this behavior during mitosis, diploid homozygous cdc7-ts cells (like cdc28-ts) initiate premeiotic DNA synthesis normally at the restrictive temperature. However, these diploids do not form a synaptonemal complex, nor do they commit to recombination or form ascospores, indicating that the cdc7 lesion affects the mitotic and meiotic pathways in a different, distinct manner (Schild and Byers, 1978) . Furthermore, the CDC7 gene has also been implicated in an error-prone DNA repair pathway as a member of the RAD6 epistasis group (Njagi and Kilbey, 1982) . Finally, Cdc7 may also be involved in transcriptional silencing of the mating type cassette right (HMR) (Axelrod and Rine, 1991) .
At present, little is known about how Cdc7 affects these different DNA processes. A clue as to the molecular function of Cdc7 was afforded by the demonstration that the open reading frame encoding CDC7 contains the 11 catalytic domains characteristic of protein kinases (Patterson et al., 1986) . We and others have shown that the Cdc7 protein isolated from vegetatively growing yeast cells is active as a kinase that phosphorylates histone Hi in vitro (Hollingsworth and Sclafani, 1990; Yoon and Campbell, 1991) . Two groups have shown by site-directed mutagenesis that Lys 76, which corresponds to the conserved lysine residue found in the ATP binding domain of all protein kinases, is essential for in vivo function, arguing that the kinase activity of Cdc7 is essential for its function in mitosis and meiosis (Buck et al., 1991; Hollingsworth et al., 1992) . In addition, the Cdc7 protein is modified by phosphorylation and is located in the nucleus (Yoon and Campbell, 1991) . The demonstration that Cdc7 is a protein kinase associated with the nuclei of mitotic cells suggests that Cdc7 may function in the mitotic cell cycle by phosphorylating pr6teins involved in the initiation of DNA synthesis and/or in the G1/S transition. Recently, Din et al. (1990) have shown that both CDC28 and CDC7 are required in vivo for phosphorylation of the 34 kDa subunit of the replication protein RP-A, and that this phosphorylation occurs at the Gl/S transition. RP-A was originally isolated from human cells in the process of fractionating cellular extracts into components capable of reconstituting SV40 DNA replication in vitro (Wobbe et al., 1987; Fairman and Stillman, 1988; Wold and Kelly, 1988) . RP-A is single stranded DNA binding (SSB) protein, essential for both the initiation and elongation reactions (Wold and Kelly, 1988; Kenny et al., 1989 Kenny et al., , 1990 . Because of its documented cell cycle specific phosphorylation pattern, RP-A is a good candidate for direct phosphorylation by either the Cdc28 or Cdc7 kinase, although there may be others as well.
Although we had some clues to the role of CDC7 from previous work, very few clues were available as to what limits CDC7 function to a specific point in the cell cycle. CDC7 is not periodically transcribed, and cells carrying a deletion of CDC7 on the chromosome can divide up to eight times after loss of a plasmid carrying the CDC7 gene (Sclafani et al., 1988) . Thus periodic activation of Cdc7 kinase rather than abundance may govern its stage-specific function. Other protein kinases are known to be regulated by association with regulatory subunits and/or phosphorylation. In this work we present evidence that Cdc7 function is, at least in part, regulated by phosphorylation.
MATERIALS AND METHODS

Strains, Media, and Plasmids
The genotypes and sources of the yeast strains used were SEY6210, a his3, leu2, lys2, suc2, trpl, and ura3 (S.D. Emr, California Institute of Technology); YC7379, a adel, his7, lys2, tyrl, ura3, and cdc7-A (Yoon and Campbell, 1991) ; CU4-1, a adel, ura3, and cdc4-1 (A.Y. Jong, University of Southern California); USC6-5, a leu2, ura3, and cdc6-1 (A.Y. Jong, University of Southern California); YC488m, a hisl, leu2, poll-17, trpl, ura3, and canl (M. Budd, California Institute of Technology); YC28, a adel, his3, ura3, and cdc28-13 (this work); G1906c, a barl-1, leul, rmel, trp5, ura3, canl, and cir+ (A.Y. Jong, University of Southern California). Cells were routinely grown in yeast extract, peptone, dextrose (YPD) medium (1% yeast extract, 2% Bacto peptone, 2% glucose) or synthetic minimal medium supplemented with amino acids and adenine but lacking uracil. Either 2% glucose, or 2% raffinose, plus 2% galactose were used as the carbon source. For in vivo 32Pi labeling, cells were grown in LPSM medium (Reneke et al., 1988) .
Escherichia coli cells were grown in 1% bacto tryptone, 0.5% bacto yeast extract, and 1% NaCl (LB) medium containing ampicillin (50 Ag/ml). To overexpress wild-type CDC7, thermolabile cdc7-1, and the CDC7-hemagglutinin fusion gene in yeast, we used a high copy number, 2 ,um containing vector pSEY18-Gal (S.D. Emr). pSEY18-Gal also contains the URA3 gene and the inducible GALI,10 promoter. pSYC758 carries wild-type CDC7 under the GALIO promoter of pSEY18-Gal (Yoon and Campbell, 1991) . pSYC7-158, carries a temperature sensitive cdc7-1 gene under the GAL1,10 promoter, and was constructed for this work as explained in detail below. pSYCHA7 carries the CDC7-hemagglutinin epitope fusion gene under the control of the GALl,1O
promoter (see below for details). The T7 promoter containing vector, pT7-7 (Tabor and Richardson, 1985) , was used to express the Cdc7-hemagglutinin epitope fusion protein in E. coli. Plasmid pSYC7-83 carries a cdc7 mutant allele with a Ser 83 to Ala change cloned in pSEY18-Gal exactly as in pSYC758.
Buffers and Inhibitors
The buffers and inhibitors used were the following: C buffer: 50 mM tris(hydroxymethyl)aminomethane (Tris), pH 7.5, 150 mM NaCl, 15% sucrose; IP buffer (immunoprecipitation buffer), 50 mM Tris-HCl at pH 7.5, 150 mM NaCl, 0.5% Tween 20, 0.2 mM EDTA, and protease inhibitors; K buffer (kinase buffer), 25 mM Tris-HCl at pH 7.5, 5 mM NaF, 15 mM MgCl2, 5 mM ethylene glycol-bis(Ql-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), and protease inhibitors; L buffer (lysis buffer), 100 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES) at pH 7.9, 0.5% sodium deoxycholate, 0.5% Triton X-100, 0.1% sodium dodecyl sulfate (SDS), 0.2 mM EDTA, 0.2 mM EGTA, 2.5 mM dithiothreitol, protease inhibitors, and phosphatase inhibitors; AP buffer (acid phosphatase buffer), 10 mM piperazine-N,N'-bis(2-ethanesulfonic acid) (PIPES) at pH 6.0 and protease inhibitors; CIP buffer (calf intestinal alkaline phosphatase buffer), 50 mM Tris-HCl at pH 8.0, 25 mM NaCl, 5 mM MgCl2, and protease inhibitors; protease inhibitors, 1 mM phenylmethylsulfonyl fluoride,
Antibodies
The production of polyclonal Cdc7 antibody is described in Yoon and Campbell (1991) . To purify the Cdc7 antibody, an affinity column was made by linking 5 mg of bacterially produced Cdc7 protein to 1 g of CNBr-activated Sepharose as recommended by Pharmacia (Piscataway, NJ). By using this Cdc7 affinity column, the antibody was purified according to the method detailed in Harlow and Lane (1988) . The monoclonal antibody 12-CA5, a subclone of H26D08 (mouse IgG 2b), was raised against the influenza hemagglutinin peptide (HA; YPYDVPDYA) as previously described by Field et al. (1988) 
Immunoprecipitations and Protein Kinase Assays
Either whole-cell or nuclear extracts were used to prepare immune complexes. The amounts of extracts and antisera used are indicated specifically in each Figure legend. Cdc7 immune complexes were prepared as previously described (Yoon and Campbell, 1991 Because we had previously shown that the N-terminal 20 amino acids were dispensable for CDC7 function in vivo (Yoon and Campbell, 1991) , we chose to add the hemagglutinin epitope (HA) to the Nterminus of the Cdc7 protein. Plasmid pTHA-CDC7 encoding the hemagglutinin epitope-Cdc7 fusion protein, called HA-Cdc7 in the text, was constructed from the plasmid pT7-CDC7. pT7-CDC7 carries the complete CDC7 gene cloned into the T7 promoter based vector pT7-7 and has a unique Nde I site which marks the initiation codon for CDC7. To construct pTHA-CDC7, the synthetic oligonucleotide 5'-T ATG TAC CCA TAC GAT GTT CCA GAT TAC GCT AGC TTG GGT GGT CC-3' encoding the HA epitope, YPYDVPDYA, and the linker sequence, SLGGP, was inserted into the Nde I site of pT7-CDC7. The linker GGP is used to connect the HA peptide to the CDC7 gene because it is expected to cause the HA peptide to protrude from the rest of the protein. Then, the junction sites of recombinant clones were sequenced to confirm the cloning procedures yielded an in-frame fusion gene.
For expression of the HA-Cdc7 fusion protein in E. coli, pTHA-CDC7 was transformed into the bacterial strain BL21 (DE3) (Studier and Moffat, 1986) . This strain carries the T7 RNA polymerase gene under the control of the lacUV5 promoter. Cells carrying pTHA-CDC7 were grown in 500 ml of LB medium supplemented with ampicillin (50 jig/ml) to an optical density (OD600) of 0.5. The polymerase, and hence the HA-CDC7 fusion gene, were induced by the addition of isopropyl ,B-D-thiogalactoside (IPTG) to a final concentration of 0.5 mM, and the culture was allowed to grow for another 3 h. Cells were harvested, resuspended in 20 ml of ice-cold 10 mM Tris-HCl at pH 7.4, 100 mM NaCl, 1 mM MgCl2, 10 gg/ml lysozyme, protease inhibitors, and disrupted by sonication with four 30-s pulses. The inclusion bodies containing the insoluble HA-Cdc7 fusion protein were isolated by centrifuging the bacterial extracts at 10 000 rpm for 10 min at 4°C in a Sorvall (Newton, CT) SS34 rotor. The pellet was Vol. 4, February 1993 resuspended in 200 mM Tris-HCl at pH 8.2, 500 mM NaCl, 0.1% Triton X-100 (Triton Diagnostics, Alameda, CA), 1 mM dithiothreitol, sonicated once for 30 s, and centrifuged again at 10 000 rpm for 10 min. The final pellet was dissolved in 50 ml of buffer A (25 mM Tris-HCI at pH 8.0, 1 mM dithiothreitol, and 6 M urea).
To purify HA-Cdc7 fusion protein, protein extracts were loaded onto 20 ml of DEAE-Cellulose (Whatman, Clifton, NJ) column that had been equilibrated with buffer A containing 25 mM NaCl. After washing the column with two column volume of buffer A with 50 mM NaCl, proteins were eluted by a linear gradient of 50-500 mM NaCl in buffer A. The HA-Cdc7 fusion protein was eluted at -250 mM NaCl, as determined by protein blotting of the fractions with Cdc7 antibody. The fractions containing the fusion protein were pooled, diluted to a protein concentration of -50 ng/,ul with buffer B (200 mM Tris-HCl at pH 8.0,500 mM NaCl, and 1 mM dithiothreitol) containing 6 M urea, and dialyzed against buffer B with 4 M urea for more than 8 h. The concentration of urea in the dialysis buffer was gradually reduced from 4 M to 2 M, 1 M, and finally 0 M. The length of dialysis in each urea concentration was for more than 8 h each. The fusion protein was judged to be >90% pure by Coomassie blue staining following SDS-polyacrylamide gel electrophoresis.
Expression of HA-CDC7 Fusion Gene in Yeast
To produce HA-Cdc7 fusion protein in yeast, pTHA-CDC7 was first digested with Nde I and Sph I. The 1.8-kb DNA containing the HA-CDC7 fusion gene was then treated with T4 DNA polymerase, EcoRI linkers were attached, and the fragment was ligated into the EcoRI site of the yeast expression vector, pSEY18-Gal. The resulting plasmid, pSYCHA7, carries HA-CDC7 gene under the control of the inducible GAL1,10 promoter and is capable of efficiently suppressing the temperature sensitive phenotype of a cdc7-1 allele at the nonpermissive temperature, 36°C. Thus the epitope does not seem to interfere with Cdc7 function in vivo when fused to the Cdc7 protein.
Cloning of the cdc7-1 Allele and Overproduction of Thermolabile cdc7-1 Protein in Yeast
The mutation in cdc7-1 has been shown to be a Gly to Ala change at amino acid position 384, between the Sac I and Sph I sites (Patterson et al., 1986; Hollingsworth et al., 1992) . The polymerase chain reaction was performed in a Perkin Elmer Cetus (Norwalk, CT) DNA Thermal Cycler by using -150 ng of yeast genomic DNA isolated from strain cdc7-1 and 5 ,tg each of the oligonucleotide primers (5' primer, 5'-TAT AAT GAG CTC AAC CTG CTG TAC ATA ATG ACG-3', where the Sac I site is underlined; 3' primer, 5'-CTT AAG CGC ATG CCA CCA ATT ATG CTA AAC CGT-3' in which the Sph I site is underlined). The plasmid containing the temperature sensitive allele, pSYC7-158, was constructed by ligation of the 1,393 bp Sac I/Sph I PCR fragment of the cdc7-1 allele into the Sac I and Sph I sites of plasmid pSYC758, which expresses wild-type Cdc7 protein from the GALIO promoter (Yoon and Campbell, 1991) . This creates an in-frame fusion of the 3'-1,393 bp of the cdc7-1 allele to the 5'-282 bp of the CDC7 gene. Clones were transformed into a heterozygous diploid, CDC7/ cdc7::Tn3, carrying a disrupted cdc7 allele, which was constructed for this test. After sporulation, the spores containing plasmids and disruptions grew but were temperature sensitive. Thus the clone complements a gene disruption and gives a temperature sensitive phenotype. As expected, the clone does not complement cdc7-1 strains at 36°C. Protein extracts were prepared from a cdc7-1 strain containing either pSYC758 (wild-type CDC7) or pSYC7-158 (ts cdc7-1). Immunoblot analysis of these extracts confirmed that the cdc7-1 protein was overproduced at the permissive temperature at the same levels as wild type (unpublished observation).
Site-Directed Mutagenesis of CDC7 (Figure 2 , lanes 3, 4, 7, and 8). When cdc28 cells were grown at the permissive temperature, 25°C, and assayed for kinase activity, normal levels of kinase were observed as shown in Figure 2 , lane 5. These findings suggest that the Cdc7 kinase is inactive before START but that passage through START provides a kinase active at least in vitro. Because substrate was provided in the in vitro assay, availability of substrate could not account for the inactivity of Cdc7 in the extracts, although such secondary factors may contribute to the overall regulation of Gl in vivo. Thus we favored the interpretation that activation of the Cdc7 kinase through posttranslational modification during the cycle was an important component of its cell cycle regulation, and sought more direct evidence that this might be the case.
Timing of Activation of the Histone Hi
Phosphorylating Activity of Cdc7 Protein Coincides with Increases in in vivo Phosphorylation Levels
We have previously reported that Cdc7 is a phosphoprotein and that this phosphorylation can be detected by in vivo 32Pi labeling of cells expressing elevated levels of Cdc7 protein (Yoon and Campbell, 1991) . To determine whether the absence of Cdc7 kinase activity coincides with absence of phosphorylation, we carried out blocking experiments similar to those in Figure 2 and characterized the phosphorylation state of Cdc7 during the block. cdc28, cdc4, cdc6, and poll strains were transformed with a plasmid expressing CDC7 under control of the GAL1,1O promoter and were labeled with 32p; in vivo during a block at the nonpermissive temperature.
[cdc6 arrests late in Gi with a phenotype similar to cdc7 (Hartwell, 1976) .] As shown in Figure 3 , Cdc7 was present as a phosphoprotein in all blocked cells (lanes 2-5). In cdc28 mutant cells, however, the amount of phosphoprotein was barely detectable in cells held at 37°C as compared with cdc28 grown at 25°C (Figure 3 --tCdc7 tivity during the cell cycle even when Cdc7 is overproduced ( Figure 1 ) and the viability of cells overproducing Cdc7 (Yoon and Campbell, 1991) .
To verify that the reduction in level of phosphorylated protein in the cdc28-arrested cells was not due to reduction in the amount of Cdc7 protein per se, an independent labeling and immunoprecipitation experiment was carried out in conjunction with a protein blot of the respective extracts. As shown in protein blot in Figure 3B , there is no difference in the abundance of the Cdc7 protein in cdc28 cells held at 360 or 25°C. Figure 3A , except phosphate depleted YPD with 2% galactose as carbon source (Moll et al., 1991) The positive correlation between the extracts in which Cdc7 protein is maximally phosphorylated and in which it is active predicted that phosphorylation might be essential for activity of the Cdc7 kinase. The histone Hi kinase activity of Cdc7 was therefore monitored after incubating Cdc7 immune complexes in the presence or absence of phosphatase ( Figure 4A ). For these experiments we used immune complexes prepared from cells overproducing native Cdc7 protein by incubation with Cdc7 antibody ( Figure 4A, lanes 1-3) . We also prepared a Cdc7-hemagglutinin fusion protein and overproduced it in yeast as described in MATERIALS AND METH-ODS. Cdc7-containing immune complexes were then prepared with the hemagglutinin monoclonal antibody, 12-CA5, which recognizes the hemagglutinin epitope ( Figure 4A, lanes 4-7) . The Cdc7 protein immunoprecipitated by the two antibodies was active as a histone Hi kinase ( Figure 4A , lanes 1 and 4). Upon phosphatase treatment, however, Cdc7 was inactivated as a kinase, as shown in Figure 4A , lanes 2, 3, and 5. The amount of Cdc7 protein remained constant under the conditions of the phosphatase treatment ( Figure 4B ), assuring that the inactivation was not due to proteolysis. Although phosphatase was removed by extensive washing before assaying for kinase, two experiments were performed to ensure that there was no residual phosphatase bound tightly to the protein A-Sepharose beads, which might interfere with the Cdc7 kinase. In Figure 4A , lane 6, a combined sample of both phosphatase-treated (1/2) and untreated (1/2) immune complexes is seen to contain about one-half of the kinase activity of that shown in Figure 4A , lane 4, confirming that phosphatase was not dephosphorylating histone Hi during the kinase reaction. In a separate experiment, okadaic acid was added to the kinase reaction following phosphatase removal to inhibit any residual phosphatase. Again, the Cdc7 kinase remained inactive ( Figure 4A , lane 7). Thus we conclude that the absence of histone Hi kinase activity in the phosphatase treated Cdc7 protein is due to removal of phosphate(s) important for kinase activity. (Yoon and Campbell, 1991) . To ask if the phosphorylation is due to Cdc7 kinase or to a coimmunoprecipitating kinase, the thermolabile cdc7-1 mutant protein was assayed for autophosphorylation. We and others have previously shown that the catalytic activity of the mutant Cdc7 kinase is thermolabile in vitro (Hollingsworth and Sclafani, 1990; Yoon and Campbell, 1991) . As shown in Figure 6 , the cdc7- had to be purified so that it could be used as a substrate. Cdc7 protein was expressed in E. coli as a fusion protein with the hemagglutinin epitope (see MATERIALS AND METHODS for details). Although a number of different conditions were tested, the bacterially produced fusion protein, designated HA-Cdc7 protein, was not active as a kinase, in contrast to that produced in yeast (see Figure  8 ). In addition, Cdc7 protein expressed in E. coli is not phosphorylated (Yoon, Loo, and Campbell, our unpublished data) . The unphosphorylated Cdc7 protein was therefore ideally useful as a substrate to test the effects of phosphorylation by Cdc28 immune complexes. Antibodies raised against the N-terminal 11 amino acids of Cdc28 protein (gift of M. Tyers and A.B. Futcher, Cold Spring Harbor, NY) were used to prepare Cdc28 immune complexes. As shown in Figure 7 , the Cdc7 fusion protein was phosphorylated by the Cdc28 immune complexes. Two controls were performed to ask if Cdc28 was responsible for the phosphorylation. First, extracts from a wild-type strain and from strain cdc28-13, extracts of which contain a thermolabile Cdc28 kinase (Reed et al., 1985; Wittenberg and Reed, 1988) , were compared as a source of Cdc28 kinase. The protein kinase reaction was carried out at the permissive (25°C) and nonpermissive temperature (38°C) for the cdc28- Figure 7 . Phosphorylation of Cdc7 protein by Cdc28 immune complexes. Whole yeast lysates were prepared from a cdc28-13 strain and a wild-type strain as described in the legend to Figure 4 . Cdc28 kinase was then immunoprecipitated from these extracts (100 ,ug each) with excess antibody (2 pl each) raised against the N-terminal 11 amino acids of Cdc28 protein (lanes 1-4 and 7-10) or with the same antibody preincubated with 30 qg of the N-terminal peptide (lanes 5, 6, 11, and 12). Cdc28 immune complexes were prepared from cdc28-13 strain in lanes 1-6 and from wild-type strain in lanes 7-12. Kinase reactions were carried out at 25°C (lanes 1, 3, 5, 7, 9, and 11) or 38°C (lanes 2, 4, 6, 8, 10, and 12) with 500 ng of HA-Cdc7 fusion protein as substrate. The fusion protein was purified out of E. coli cells as explained in MATERIALS AND METHODS. In lanes 3, 4, 9, and 10, Cdc28 immune complexes were incubated in the absence of the fusion protein. Products were analyzed by electrophoresis on a 10% SDSpolyacrylamide gels, which were run until the 30-kDa marker protein reached the bottom. The HA-CDC7 band was identified by staining of the gels with Coomassie blue. The 500 ng of HA-Cdc7 fusion protein was the major band and was absent where HA-Cdc7 was omitted from the experiment. Lanes 1-6 were run on one gel and lanes 7-12 on another gel. The experiments with the cdc28-13 extract were repeated 4 times. Figure 7 demonstrates that there was less Cdc7 phosphorylating activity in the immune complexes prepared from strain cdc28-13 at 38°C than at 25°C. In contrast, immune complexes from the wild-type strain, while less active overall, were more active at 38°C than at 25°C (lanes 7 and 8). As a second control, the 11 amino acid, Cdc28-derived peptide employed as immunogen was used as competitor in the immunoprecipitation. Cdc7 was not phosphorylated when the Cdc28 antibody was preincubated with the Cdc28-peptide (Figure 7, lanes 5, 6, 11, and 12) . Thus the in vitro phosphorylation is likely due to the Cdc28 protein.
Additional proteins were phosphorylated by the Cdc28 immune complexes as shown in Figure 7 . None of these proteins appeared to be phosphorylated in a Cdc28-specific way, because the level of phosphorylation was the same at either temperature or the kinase activity was thermolabile even in the wild-type strain. However, the -62 kDa band present above the HACdc7 protein could represent a coprecipitating cyclin.
Similar results to those shown in Figure 7 have been obtained by using p13 beads (gift of W.G. Dunphy and Newport, 1989) and Cksl antibodies (gift of C. Wittenberg) (unpublished observation) to prepare the Cdc28 kinase. CKS1 encodes the S. cerevisiae p13 analog and Cksl antibodies have been shown to coimmunoprecipitate active Cdc28 kinase along with Cksl protein (Hadwiger et al., 1989a) . Because the enzymological specificity of Cdc28 present in Cdc28 kinases prepared with these different reagents has not been characterized, we cannot yet derive any information about which of the postulated forms of Cdc28 kinase is active in our experiments.
The phosphorylation by Cdc28 in vitro is not efficient enough currently to allow mapping of the peptide(s) directly phosphorylated by the Cdc28-like activity. This appears to be due to difficulty and lack of reproducibility in refolding the protein purified from E. coli (see MA-TERIALS AND METHODS). We have been unable to increase the level of phosphorylation of HA-Cdc7 fusion protein as compared with that of other proteins, due to difficulties thus far in obtaining concentrated HA-Cdc7 protein in soluble form. The fusion protein precipitates at concentrations >50 ng/,l under reaction conditions tested thus far. Although we have not been able to achieve the sensitivity necessary to carry out phosphopeptide analysis of the Cdc7 protein phosphorylated in vitro, an alternative approach to gaining information about the amino acid site phosphorylated by the Cdc28 immunoprecipitates is provided by the ability to express a mutant Cdc7 protein with an altered Cdc28 consensus recognition site in yeast. A two-dimensional phosphotryptic peptide map of Cdc7 protein containing a mutation of Ser 83 to Ala, in the putative Cdc28 consensus recognition site, is shown in Figure 5B . Comparison to the wild-type protein in Figure 5A shows that there is a major alteration in the phosphorylation pattern; two spots are greatly reduced in intensity and a third spot is missing. Protein blotting verifies that the amount of mutant protein in extracts is identical to that of wild type (Loo and Campbell, unpublished observations). Thus the in vivo pattern suggests that alteration of the consensus site for Cdc28 phosphorylation has a dramatic effect on more than one phosphorylation site on the Cdc7 protein. We cannot make a definitive statement about how many phosphorylation sites are affected until we know whether the three spots in wild type arise due to multiple, distinct phosphorylation sites or due to incomplete typtic digestion. Further studies will be required to show if this biochemical result reflects the physiological situation. Phosphorylation of Cdc7 Protein by Cdc28 Activates the Cdc7 Kinase To test whether phosphorylation of Cdc7 by Cdc28 is sufficient to activate the inactive bacterially produced Cdc7 protein, we designed an experiment in which we first phosphorylated highly purified, soluble, bacterially produced HA-Cdc7 protein with cold ATP with Cdc28 immune complexes from crude yeast extracts. We then removed the Cdc28 kinase and assayed the ability of the Cdc7 kinase to phosphorylate histone Hi. To insure that Cdc28 could not participate in the histone Hi phosphorylation reaction, we used extracts prepared from a cdc28-13 strain that is known to produce a kinase that is thermolabile in vitro. The first reaction was carried out at 23°C, where the cdc28-13 kinase is active, and the second was carried out at 37°C, where the cdc28-13 kinase is not active. If wild-type CDC28 extracts were used, sufficient Cdc28 kinase activity remained in the supernatant so that even in the control without HA-CDC7 protein added, there was some histone Hi kinase activity. As shown in Figure 8 , HA-Cdc7 kinase produced in E. coli is active only after treatment with Cdc28 kinase (compare lanes 2 and 3). Inclusion of the Cdc28 peptide during preparation of Cdc28 immune complexes abolished the activation (lane 3) and activation was severely reduced at high temperature when cdc28-13 was used as source of the Cdc28 protein (lane 4). Thus we conclude that Cdc7 phosphorylation by Cdc28 can activate the kinase activity, though potential contribution of other components in the Cdc28 immunoprecipitates does not allow the conclusion that Cdc28 is sufficient to activate Cdc7. [A report, that might appear to conflict with our findings, that Cdc7 was active as a kinase when prepared in an in vitro translation system, in which posttranslational modification is not expected to occur, could be explained by the adventitious presence of a Cdc28-like kinase in the translation kit (Bahman et al., 1988 (Patterson et al., 1986; Hollingsworth and Sclafani, 1990; Yoon and Campbell, 1991) provided us with an assay for factors that contribute to the regulation of the Cdc7. Biochemical experiments showed that Cdc7 kinase activity fluctuates in the cell cycle with a periodicity coinciding with the in vivo function of Cdc7, but the steady-state protein levels remain constant, suggesting that it is the kinase activity of Cdc7 that is responsible for its essential role and that it is activation rather than abundance that accounts for cell cycle variation. In addition, we showed that Cdc7 kinase activity is undetectable in extracts of cells arrested before START, either by an a-factor block or by a cdc28 mutation, and found that this corresponds to a period when the Cdc7 protein is hypophosphorylated compared with any other point in the cell cycle. Combined with the fact that dephosphorylation of Cdc7 in vitro reduces the kinase activity to pre-START levels, these findings suggest that phosphorylation plays a role in regulating Cdc7 function. In an effort to specify the important phosphorylation events, we then showed that there are at least four tryptic phosphopeptides in Cdc7 protein populations. Both autophosphorylation and phosphorylation in trans by a protein in yeast extracts occur. The ubiquitous protein kinase, Cdc28 kinase, is at least one protein that can phosphorylate Cdc7 protein in vitro. These observations raise many interesting questions about the timing of multiple phosphorylations of Cdc7, the role of individual phosphorylations and their interdependence and whether Cdc7 is a substrate of the Cdc28 kinase in vivo.
Timing of Cdc7 Function in the Cell Cycle Early work from the Hartwell laboratory defined three genes necessary for the initiation of DNA replication, CDC28, CDC4, and CDC7, as discussed in the INTRO-DUCTION. CDC28 functions at START, and after return of cdc28 mutants from the nonpermissive temperature the cells can still adopt the alternative pathway of conjugation. Several more genes that have this phenotype have been identified but as yet have not been well studied. Three additional genes that affect START, CLN1, 2, and 3, are apparently involved in a positive feedback loop controlling the activation of the CDC28 gene product (Cross and Tinkelenberg, 1991; Dirick and Nasmyth, 1991) . These genes were identified either as suppressors of cdc28 mutations (CLN1, CLN2) or as dominant gain of function mutations (CLN3) (Sudbery et al., 1980; Cross, 1988; Nash et al., 1988; Hadwiger et al., 1989b) and have at least partially redundant functions, in that one CLN gene can compensate for loss of the other, but loss of all three is lethal (Richardson et al., 1989) . The CLN genes encode proteins that are distantly related to the cyclins that activate the p34/cdc2+/MPF kinase for induction of mitosis in Xenopus, S. pombe and other organisms. By analogy, it has been proposed that CLN1, 2, and 3 interact with and activate the Cdc28 kinase subunit and passage through START (Richardson et al., 1989; Wittenberg et al., 1990 ; see also Cross, 1988; Nash et al., 1988 and for review Nasmyth, 1990) . The molecular nature of the events set in motion by these START genes, however, has been more difficult to define.
Morphological analysis of single and double mutants and reciprocal shift studies suggest CDC7 acts subsequent to CDC28/START (Hereford and Hartwell, 1974) . In addition to CDC4 and CDC7, three other genes, CDC34, DBF4, and possibly DBF2 also function in the post-START/pre-DNA synthesis period (Johnston and Thomas, 1982; Goebl et al., 1988; Chapman and Johnston, 1989; Johnston et al., 1990) . These dependent genetic relationships predicted that activation of the Cdc7 protein should be dependent on completion of START. In keeping with this, we found that Cdc7 kinase was inactive in extracts of cells arrested at START-either by a-factor or by a cdc28 arrest. We then found that after release from a block and passage through START the kinase activity increased, decreased abruptly late in the cell cycle, and then rose again in Gl in the second cell cycle. This temporal correlation of appearance of kinase activity and in vivo function adds to the argument, previously based solely on site-directed mutagenesis (Buck et al., 1991; Hollingsworth et al., 1992) , that the kinase activity of Cdc7 is related to its essential and periodic function.
Genetic studies predicted that Cdc7 activity might be dependent on CDC4, also. The results in Figure 2 suggest that, on the contrary, the Cdc7 kinase is already active even before CDC4 completes its function. Why does CDC7 appear to depend upon the completion of CDC4 in vivo? One possibility is that the substrates of Cdc7 kinase may not be available during the cdc4 block. According to the results of Hereford and Hartwell (1974) , cdc4 mutants blocked and released in the presence of the protein synthesis inhibitor cycloheximide do not enter S phase. Further protein synthesis is thus necessary after the CDC4 step. Proteins newly synthesized after the CDC4 step may include replication proteins that require the Cdc7 kinase for posttranslational activation. Alternatively, substrates of Cdc7 kinase may exist during the cdc4 block, but somehow may be inaccessible to Cdc7 protein until after CDC4 has functioned. A third possibility is that Cdc7 kinase, like many other kinases, actually consists of two subunits, a catalytic subunit and a regulatory subunit whose abundance or modification is dependent on CDC4 function. We feel that it is likely that Cdc7 does have a regulatory subunit that enhances activity and is encoded by a second yeast gene, since we have recently been able to purify an active Cdc7 kinase from yeast and have found that Cdc7 copurifies with an 80-kDa protein, though we have not yet determined whether this 80-kDa protein represents another substrate or an essential cofactor for Cdc7 activity (Loo and Campbell, unpublished observations). We also observe an 80-kDa protein in Cdc7 immunoprecipitates from yeast (see Figure 3 , Yoon and Campbell, 1991) . Genetic suppression of cdc7 by overproduction of DBF4 and vice versa could also be interpreted as indicating that the Cdc7 kinase has a second subunit (Kitada et al., 1992) .
How is the timing of Cdc7 action controlled? One component of the regulation seems to be phosphorylation of Cdc7 protein. Phosphatase treatment of Cdc7 kinase abolishes its histone Hi kinase activity ( Figure   4 ). In addition, its phosphorylation state correlates well in the cell cycle with the time when it is active (Figures  2 and 3 ). It appears likely from our studies that Cdc28 kinase provides at least one essential phosphate modification (Figures 5 and 6 ). We also know that Cdc7 is phosphorylated by at least one other kinase, in that Cdc7 appears to autophosphorylate (Figure 3 in Yoon and Campbell, 1991;  and this work Figure 6 ). Krek and Nigg (1991) found that it is probably Thr 161 that is phosphorylated in M phase and pointed out that Thr 161 is located within a conserved domain which in other kinases is subject to autophosphorylation (Hanks et al., 1988) . Furthermore, they referred to the fact that the cognate amino acid, Thr 167, in S. pombe cdc2 kinase is essential for function and is phosphorylated. The corresponding residue in Cdc7 kinase is Thr 281, located in region VIII of the canonical protein kinase active site (Hanks et al., 1988) . Buck et al. (1991) have shown by site-directed mutagenesis that either a serine or a threonine at this position is essential for the in vivo functions of CDC7. Therefore, we predict that Thr 281 may be the site of autophosphorylation and that phosphorylation of this site may be required for full Cdc7 activity. We note, however, that Xenopus p34CdC2, which requires phosphorylation of Thr 161 for activation, does not appear to autophosphorylate but rather to be phosphorylated in trans (Solomon et al., 1992) .
Is CDC7 a Physiological Substrate of CDC28? We have shown that Cdc28 immunoprecipitates can phosphorylate and even activate the histone Hi phosphorylating activity of Cdc7 kinase in vitro and that Cdc7 kinase is inactive in cells blocked by a cdc28 mutation. In keeping with our proposal that autophosphorylation is necessary for activity, then phosphorylation by the "Cdc28" kinase may change the conformation of Cdc7 to a state that allows autophosphorylation of an additional essential site. It has been shown for several kinases that phosphorylation of one site can influence sequential phosphorylation of other sites (see Roach, 1991 , for complete discussion of multisite and hierarchical protein phosphorylation). Indeed, our phosphopeptide analysis suggests that there may be at least four phosphoamino acids on the Cdc7 protein. Krek and Nigg (1991) have discovered four phosphorylation sites on mammalian p34cdc2 and have shown that each one is cell cycle regulated: Thr 14 and Tyr 15 are phosphorylated in G2; Thr 161, probably, is phosphorylated in M, and Ser 277 phosphorylation peaks in Gl. All probably contribute to the regulation of the enzyme. Considering the multiple functions of Cdc7, similar complex regulation is not unlikely.
Although we also favor a multisite phosphorylation scenario for Cdc7, we by no means claim that our results establish Cdc7 as a substrate of Cdc28 in vivo. Given the nature of cell cycle mutants, one could argue that the effect of the cdc28 mutation is indirect. Another intermediate kinase may be required or an essential cofactor may not become available until after START. For instance, Solomon et al. (1992) have shown that Xenopus p34cdc2 must associate with cyclin to be phosphorylated on Thr 161. Therefore the reduction in phosphorylation in the cdc28 mutant does not constitute an argument that Cdc28 is a Cdc7 kinase in vivo. Furthermore, our demonstration that phosphorylation of Cdc7 in vitro by Cdc28 activates Cdc7 kinase is important, but it is inconclusive in the sense that it only demonstrates that the kinase active in vivo must have the same specificity as Cdc28. The consensus motif for a cdc2+/Cdc28 phosphorylation site has been reported to be S/T-P-X-Z (where X is a polar amino acid, and Z is generally a basic amino acid) (for reviews, see Lewin, 1990; Moreno and Nurse, 1990 and Pines and Hunter, 1990 Roach, 1991) . Cdc7 contains three SP or TP sites which lie in the C terminal half of Cdc7. Mutations of the respective serines and threonines in these positions have no effect on in vivo function (Loo, Yoon, and Campbell, unpublished observations) .
Recently, three criteria have been set for establishing a protein as the physiological substrate of a particular kinase (Lewin, 1990) . First, the amino acid phosphorylated by the kinase in vitro should be occupied in vivo at the point in the cell cycle when it is needed. Second, mutations, either in the kinase or in its recognition site in the substrate or both, should block phosphorylation in vivo. Third, some function of the protein should be altered by phosphorylation. To identify the kinases that phosphorylate Cdc7 and their sequence of action will require much more work: mapping of specific phosphorylation sites, determination of function of specific phosphorylation events by site directed mutagenesis, evaluation of phosphopeptide maps in protein kinase mutants and purification of the kinases responsible. Only when all this work is done will we be able to answer whether and or how sequential phosphorylation influences Cdc7's various in vivo functions.
